Advances in Care

NewYork-Presbyterian
  • 0.0 (0)
  • MEDICINE
  • EVERY TWO WEEKS

On Advances in Care, epidemiologist and science communicator Erin Welsh sits down with physicians from NewYork-Presbyterian hospital to discuss the details behind cutting-edge research and innovative treatments that are changing the course of medicine. From breakthroughs in genome sequencing to the backstories on life-saving cardiac procedures, the work of these doctors from Columbia & Weill Cornell Medicine is united by a collective mission to shape the future of health care and transform the lives of their patients. Erin Welsh, who also hosts This Podcast Will Kill You, gets to the heart of her guests’ most challenging and inventive medical discoveries. Advances in Care is a show for health careprofessionals and listeners who want to stay at the forefront of the latest medical innovations and research. Tune in to learn more about some of medicine’s greatest leaps forward. For more information visit nyp.org/Advances

  1. How ECMO Leadership is Driving Improved Survival and Post-ICU Recovery

    19 MAR

    How ECMO Leadership is Driving Improved Survival and Post-ICU Recovery

    On this episode of Advances in Care, Erin Welsh is joined by Dr. Cara Agerstrand, director of the Medical ECMO Program at NewYork-Presbyterian and Columbia, and Dr. Matthew Baldwin, critical care specialist at NewYork-Presbyterian and research lead of Columbia’s Baldwin Lab which focuses on the study of critical illness survivorship.  Thousands of people suffer from cardiopulmonary conditions such as cardiac arrest and severe respiratory illnesses in the United States every year, with many requiring mechanical ventilation and critical care in the ICU. To better serve these patients, NewYork-Presbyterian and Columbia has built a renowned program to manage these patients on rescue therapies like extra-corporeal membrane oxygenation (ECMO), the most advanced form of cardiopulmonary life support. Since 2009, the team at NewYork-Presbyterian and Columbia has established an expertise to care for the sickest respiratory and cardiac failure patients with this technology, and has been at the forefront of utilization which has rapidly evolved from early pediatric use to post H1N1 and COVID surges.  The standards of care for ECMO treatment and patient outcomes set by New York Presbyterian and Columbia over the past decade has earned them recognition as an ELSO Platinum Level Center of Excellence, one of only a few centers worldwide to have consistently achieved this status since it was first awarded. The team takes this expertise further through advanced research in The Baldwin Lab, which focuses on a variety of projects to better understand the biological factors of why some patients fully recover from ICU stays and others do not, as well as physical, mental, and emotional wellbeing for patients. *** Dr. Cara Agerstrand is an Associate Professor of Medicine and Director of the Medical ECMO Program at Columbia University Irving Medical Center / NewYork-Presbyterian Hospital. Dr. Agerstrand completed her Internal Medicine residency and Pulmonary & Critical Care fellowship at Columbia University Irving Medical Center. She is an elected member of the Steering Committee of the Extracorporeal Life Support Organization, a member of the ECMO and Mechanical Circulatory Support Domain Task Force of the American College of Chest Physicians and is extensively involved in clinical care, research, and educational efforts involving extracorporeal membrane oxygenation (ECMO) and extracorporeal carbon dioxide removal (ECCO2R). She has special interests in the use of ECMO for severe forms of the acute respiratory distress syndrome (ARDS), pulmonary hypertension and in pregnant and postpartum patients. Dr. Agerstrand is widely published and is an internationally invited speaker. Dr. Matthew Baldwin, MD, MS, is a board-certified pulmonary and critical care physician and clinical investigator with a Masters in Biostatistics. Dr. Baldwin’s laboratory aims to improve critical illness survivorship. His research into survivors of acute respiratory failure works to elucidate the mechanisms of post-ICU frailty as therapeutic targets for improving physical recovery. He has identified frailty subtypes in acute respiratory failure survivors, and discovered that aging-related plasma biomarkers of inflammation, neuro-endocrinopathy, and muscle mitochondrial myopathy are potential therapeutic targets for post-ICU interventions. His research related to palliative care aims to improve ICU survivorship, and he has developed novel palliative care interventions for mechanical ventilation patients, such as chaplain-led communication-board-guided spiritual care. For more information visit nyp.org/Advances

    20 min
  2. Phase 3 Trial Reduces Risk of Progression in Metastatic Prostate Cancer

    5 MAR

    Phase 3 Trial Reduces Risk of Progression in Metastatic Prostate Cancer

    On this episode of Advances in Care, host Erin Welsh is joined by Dr. Scott Tagawa, medical oncologist at NewYork-Presbyterian and director of the Genitourinary Oncology Program at Weill Cornell Medicine, to talk about the latest developments in prostate cancer care.  Prostate cancer is the most common cancer in men after skin cancer, with 5-10% of patients presenting with metastasis at the time of diagnosis. Advancing treatment options for men with metastatic disease remains a critical priority in oncology. To address this challenge, Dr. Tagawa recently led a promising Phase III randomized trial– called PSMAddition– to assess radioligand therapy, a subset of targeted radionuclide therapy, or TRT. This new therapeutic agent, lutetium PSMA-617, is being tested in men with hormone-sensitive metastatic prostate cancer. Radioligand therapy works by seeking prostate-specific membrane antigens (PSMAs) to deliver radiation to prostate cells throughout the body while minimizing surrounding damage that other therapies can sometimes cause. The results from the PSMAddition trial were significant. The addition of TRT in addition to standard hormone treatment slowed cancer progression by 28%, yielded notable declines in PSA levels, and proved benefits across patient subgroups. The PSMAddition trial is the first to analyze the use of this treatment regimen earlier in care and could potentially redefine the standard of care for patients with metastatic prostate cancer.  While metastatic prostate cancer remains incurable, combination strategies incorporating PSMA-targeted therapy represent a promising pathway for expanding the quality and quantity of life for patients, and may prove beneficial as a first-line treatment.  This breakthrough trial builds on 25 years of innovation in prostate cancer research at NewYork-Presbyterian and Weill Cornell Medicine, where foundational discoveries helped advance the development of PSA and PSMA-targeting agents that are now transforming cancer care. *** Scott T. Tagawa, MD, MS, FACP, FASCO, is a Professor of Medicine and Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center. His research covers clinical and translational investigations in genitourinary tumors and thrombosis (blood clotting) in people with cancer. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theranostics in prostate cancer. Dr. Tagawa also serves as leader of the GU Disease Management Team and co-leader of the Experimental Therapeutics Program of the Meyer Cancer Center. He is the WCM principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. For more information visit nyp.org/Advances

    16 min
  3. Breakthrough Technology Improves Concussion Assessment and Player Safety

    19 FEB

    Breakthrough Technology Improves Concussion Assessment and Player Safety

    On this episode of Advances in Care, host Erin Welsh sits down with Dr. Thomas Bottiglieri, chief of the primary care sports medicine division at NewYork-Presbyterian and Columbia, to discuss the evolving landscape of concussion care– from prevalence to emerging diagnostic breakthroughs.  With over 2 million estimated concussions occurring annually in the United States, and many of them affecting young athletes, Dr. Bottiglieri and his colleagues have sought to develop a more accurate and accessible way to objectively diagnose concussion. While a single injury may not cause long term issues, research shows that repeated head trauma– and lack of proper care– can lead to premature neurodegeneration.  During their research to improve diagnostic measures, Dr. Bottiglieri and his team discovered a biomarker associated with severe concussions: a subtle tremor of the head and neck that becomes amplified when a concussed patient tries to visually focus on a target.  This discovery led to the development of ProScope, an innovative eyetracking software tool that measures head and neck stability and can detect the diagnostic biomarker with over 80% sensitivity. With the advent of these tools, clinicians can now, for the first time, objectively measure concussion. A former competitive athlete himself, Dr. Bottiglieri hopes that the ProScope tool can become commercially available to improve access to cost-effective diagnosis, ensuring that athletes– or anyone with a head injury– can recover safely and return to the activities they love.  *** Thomas S. Bottiglieri, D.O. is a sports medicine physician specializing in the management of orthopedic injuries and disorders impacting athletes at all skill levels from adolescents to seniors. In addition to treating the full spectrum of muscle, bone, tendon, and joint injuries, Dr. Bottiglieri is a nationally recognized expert in the field of concussion care. His practice stresses shared decision-making with patients and their families and uses the latest medical technology, evidence-based sports medicine, and a compassionate, patient-centered approach. For more information visit nyp.org/Advances

    17 min

  4. 18/12/2025

    2025 Year in Review: Revisiting the Top Takeaways from Advances in Care

    On the final episode of 2025, host Erin Welsh is joined by Courtney Allison, host of NewYork-Presbyterian’s health and wellness podcast, Health Matters, to recap the year’s highlights from their dozens of conversations with clinicians, researchers, and health care specialists from Columbia & Weill Cornell Medicine. They highlight key takeaways, revisit groundbreaking treatments that were pioneered across the institution, and discuss several research updates that are shaping the future of medicine for both physicians and patients.   For more information visit nyp.org/Advances

    20 min

  5. 04/12/2025

    Revisiting the Network Effect: Analyzing Brain Structures to Treat Depression

    For any patient diagnosed with depression for the first time, the recommended course of treatment is the same: a medication like a selective serotonin reuptake inhibitor (SSRI), an evidence based psychotherapy, or both. But there is a large group of people for whom these treatments simply won't work. That’s where Dr. Conor Liston and his team focus. In this episode from the Advances in Care archives, Dr. Liston speaks with former host Catherine Price about his work mapping the brain is helping doctors better understand where depression is impacting certain brain structures and what that means for the symptoms patients present. Dr. Liston’s work is focused on identifying how these symptoms impact patients' brains and using those findings to identify the best treatment approach. Since this episode aired, Dr. Liston and his colleagues have continued to build on their research regarding a specific region of the brain called the “salience network.” They found that the salience network was considerably larger in people with clinical depression than in those without, and that people with larger salience networks in childhood were more likely to develop depression later in life. Their research points to an enlarged salience network as the first objective biomarker for diagnosing depression, which could revolutionize how depression is treated, and allow for intervention even before symptoms develop.

    27 min

  6. 13/11/2025

    Revisiting Deep Learner: Building AI to Improve Cardiovascular Care

    In this episode from the Advances in Care archives, Dr. Pierre Elias sits down with Catherine Price to talk about how utilizing technologies like artificial intelligence and machine learning can help diagnose patients even before symptoms develop, and support doctors by freeing them up to focus on providing personalized care to their patients. They discuss navigating bias in both artificial intelligence and clinical care, and how new technology will improve the future of medicine. Since this episode aired, Dr. Elias and his collaborators expanded their research involving AI and cardiac care, developing tools for detecting mitral regurgitation and heart failure. Additionally, a team at NewYork-Presbyterian and Columbia used AI as a fertility treatment for azoospermia, and NewYork-Presbyterian deepened its commitment to developing applications of AI in medicine through a $2 billion campaign to invest in talent and technology. For more information visit nyp.org/Advances

    31 min

  7. 30/10/2025

    Revisiting Surgical Robot: Advancing Medicine with Robot-Assisted Technology

    With perspectives spanning hepatobiliary, gynecologic, and cardiac surgeries, NewYork-Presbyterian’s Dr. Jason Hawksworth (Columbia), Dr. Tamatha Fenster (Weill Cornell Medicine), and Dr. Arnar Geirsson (Columbia) describe how they each came to incorporate robotics into their practices. One of the biggest takeaways: robotic surgeries allow for more accuracy in minimally-invasive approaches; so patients experience shorter hospital stays and quicker recoveries, even after major procedures. But there are some limitations to robotic surgeries that the doctors are still navigating. Dr. Fenster discusses how there are haptics limitations in robotic surgery. As a result, she shares more about her innovative smartHER 3D MRI program that is addressing this issue and details how her and her team are developing a way of holographically projecting 3D MRIs over patients to help guide surgeons while they operate. Since this episode aired, a team at Weill Cornell Medicine performed the first fully robotic liver transplant in the state of New York, and the Robotic Cardiac Surgery Program at NewYork-Presbyterian and Columbia completed over 100 robotic heart surgeries. Additionally, Dr. Tamatha Fenster put smartHER 3D MRI technology into practice. For more information visit nyp.org/Advances

    35 min

  8. 16/10/2025

    Revisiting Heartmaker: Revolutionizing Pediatric Heart Surgery

    Catherine Price and Dr. Emile Bacha, Chief of the Division of Cardiac, Thoracic, and Vascular Surgery at NewYork-Presbyterian/Columbia discuss the history of heart surgery, ventricular assist devices, and a new frontier in cardiac surgery: The Total Artificial Heart. Dr. Bacha tells the groundbreaking story of successfully fitting a pediatric patient with a Total Artificial Heart. He explains the nuances of the procedure, and how a backpack-powered heart gave his pediatric patient another chance. In 2023, Dr. Bacha led a team to complete the first domino infant partial heart transplant in the world. Surgeons in his division also completed the first split-root domino transplant in the northeast, saving the lives of three young patients. Most recently, Dr. Bacha became the 106th president of the American Association for Thoracic Surgery. For more information visit nyp.org/Advances

    25 min
See All (54)

Trailers

About

On Advances in Care, epidemiologist and science communicator Erin Welsh sits down with physicians from NewYork-Presbyterian hospital to discuss the details behind cutting-edge research and innovative treatments that are changing the course of medicine. From breakthroughs in genome sequencing to the backstories on life-saving cardiac procedures, the work of these doctors from Columbia & Weill Cornell Medicine is united by a collective mission to shape the future of health care and transform the lives of their patients. Erin Welsh, who also hosts This Podcast Will Kill You, gets to the heart of her guests’ most challenging and inventive medical discoveries. Advances in Care is a show for health careprofessionals and listeners who want to stay at the forefront of the latest medical innovations and research. Tune in to learn more about some of medicine’s greatest leaps forward. For more information visit nyp.org/Advances

Information

  • Creator
    NewYork-Presbyterian
  • Years Active
    2023 - 2026
  • Episodes
    54
  • Rating
    Clean
  • Copyright
    © 2023 NewYork-Presbyterian Hospital
  • Show Website
    Advances in Care

You Might Also Like